Anticarcinogenic Agents/pharmacology; Dinoprostone/metabolism; Genistein/pharmacology; Isoflavones/pharmacology; Prostatic Neoplasms/drug therapy; Biomarkers, Tumor/genetics; Biomarkers, Tumor/metabolism; Blotting, Western; Cell Proliferation/drug effects; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21/genetics; Cyclin-Dependent Kinase Inhibitor p21/metabolism; Cyclooxygenase 2/genetics; Cyclooxygenase 2/metabolism; Double-Blind Method; Gene Expression Regulation, Neoplastic/drug effects; Humans; Hydroxyprostaglandin Dehydrogenases/genetics; Hydroxyprostaglandin Dehydrogenases/metabolism; Luciferases/metabolism; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent/drug therapy; Neoplasms, Hormone-Dependent/metabolism; Neoplasms, Hormone-Dependent/pathology; Pilot Projects; Promoter Regions, Genetic; Prostatectomy; Prostatic Neoplasms/metabolism; Prostatic Neoplasms/pathology; RNA, Messenger/genetics; RNA, Messenger/metabolism; Receptors, Prostaglandin/genetics; Receptors, Prostaglandin/metabolism; Signal Transduction; Soy Foods; Transfection